{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T16:30:37Z","timestamp":1770481837470,"version":"3.49.0"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Stroke"],"published-print":{"date-parts":[[1995,12]]},"abstract":"<jats:p>\n            <jats:italic>Background and Purpose<\/jats:italic>\n            To improve the assessment of cerebral vasoreactivity using acetazolamide (ACZ), we studied the time course of the response and the relationship between dose, response, and serum concentration.\n          <\/jats:p>\n          <jats:p>\n            <jats:italic>Methods<\/jats:italic>\n            Blood flow velocities were measured with the use of transcranial Doppler ultrasonography in one of the middle cerebral arteries of 48 healthy subjects after the intravenous administration of 1 to 1.6 g ACZ. In 34 subjects (group 1), velocities were measured every second minute to detect the maximum middle cerebral artery velocity increase. We also measured regional cerebral blood flow using single-photon emission computed tomography in 27 of the subjects in group 1 before and approximately 15 to 20 minutes after the ACZ injection. The serum concentration of ACZ was measured in 15 subjects. In the remaining 14 subjects (group 2), middle cerebral artery velocity measurements were made 10, 25, 30, and 45 minutes after ACZ administration to obtain information regarding the late time course of the response.\n          <\/jats:p>\n          <jats:p>\n            <jats:italic>Results<\/jats:italic>\n            In group 1 the plateau phase of the velocity response was reached 8 to 15 minutes after ACZ administration. A large range of velocity increase was observed, and a significant correlation was found between the maximum velocity increase and the dose and serum concentration of ACZ. In group 2 subjects, maximum velocities were maintained 30 minutes after the injection, but after 45 minutes velocities had decreased to 68% of their highest level. No significant relationship was found between dose or serum concentration of ACZ and the regional cerebral blood flow increase. The velocity increase after ACZ was similar in both older and younger subjects.\n          <\/jats:p>\n          <jats:p>\n            <jats:italic>Conclusions<\/jats:italic>\n            This study shows that cerebral vasoreactivity is best assessed 10 to 30 minutes after ACZ administration and that the dose should probably exceed 15 mg\/kg if a maximum vasodilatory response in the cerebral circulation is to be obtained.\n          <\/jats:p>","DOI":"10.1161\/01.str.26.12.2302","type":"journal-article","created":{"date-parts":[[2011,6,17]],"date-time":"2011-06-17T20:08:03Z","timestamp":1308341283000},"page":"2302-2306","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":78,"title":["Cerebral Vasoreactivity Assessed With Transcranial Doppler and Regional Cerebral Blood Flow Measurements"],"prefix":"10.1161","volume":"26","author":[{"given":"Arve","family":"Dahl","sequence":"first","affiliation":[{"name":"From the Department of Neurology (D.R., R.N.-H., E.K.) and Institute for Clinical Biochemistry (K.R.), Rikshospitalet, The National Hospital, University of Oslo, and the Department of Neurology (A.D.), University Hospital, Troms\u00f8, Norway."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Russell","sequence":"additional","affiliation":[{"name":"From the Department of Neurology (D.R., R.N.-H., E.K.) and Institute for Clinical Biochemistry (K.R.), Rikshospitalet, The National Hospital, University of Oslo, and the Department of Neurology (A.D.), University Hospital, Troms\u00f8, Norway."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kjell","family":"Rootwelt","sequence":"additional","affiliation":[{"name":"From the Department of Neurology (D.R., R.N.-H., E.K.) and Institute for Clinical Biochemistry (K.R.), Rikshospitalet, The National Hospital, University of Oslo, and the Department of Neurology (A.D.), University Hospital, Troms\u00f8, Norway."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rolf","family":"Nyberg-Hansen","sequence":"additional","affiliation":[{"name":"From the Department of Neurology (D.R., R.N.-H., E.K.) and Institute for Clinical Biochemistry (K.R.), Rikshospitalet, The National Hospital, University of Oslo, and the Department of Neurology (A.D.), University Hospital, Troms\u00f8, Norway."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilia","family":"Kerty","sequence":"additional","affiliation":[{"name":"From the Department of Neurology (D.R., R.N.-H., E.K.) and Institute for Clinical Biochemistry (K.R.), Rikshospitalet, The National Hospital, University of Oslo, and the Department of Neurology (A.D.), University Hospital, Troms\u00f8, Norway."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"e_1_3_2_1_2","doi-asserted-by":"publisher","DOI":"10.1161\/str.23.2.1561643"},{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.3171\/jns.1993.79.4.0483"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1161\/str.17.6.3492787"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1161\/str.21.7.2368103"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1161\/str.19.8.3135641"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1161\/str.23.1.1731414"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.1967.47.4.595"},{"key":"e_1_3_2_8_2","unstructured":"Wistrand PJ Lindqvist A. Design of carbonic anhydrase inhibitors and the relationship between the pharmacodynamics and pharmacokinetics of acetazolamide. In: Botr\u00e9 F Gros G Storey B eds. Carbonic Anhydrase: From Biochemistry and Genetics to Physiology and Clinical Medicine. VCH Verlagsgesellschaft: Weinheim Germany; 1991:352-374."},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.3171\/jns.1987.67.4.0525"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.3171\/jns.1982.57.6.0769"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004728-198004000-00022"},{"key":"e_1_3_2_12_2","first-page":"97","volume":"184","year":"1986","unstructured":"Rootwelt K, Dybevold S, Nyberg-Hansen R, Russell D. Measurement of cerebral blood flow with Xe-133 inhalation and dynamic single photon emission computed tomography: normal values. Scand J Clin Lab Invest Suppl.. 1986;184:97-105.","journal-title":"Scand J Clin Lab Invest Suppl."},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(00)80266-2"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI111579"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0026-2862(80)90020-5"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1748-1716.1983.tb07202.x"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/jcbfm.1993.92"},{"key":"e_1_3_2_18_2","first-page":"H954","volume":"258","year":"1990","unstructured":"Friberg L, Kastrup J, Rizzi D, Jensen JB, Lassen NA. Cerebral blood flow and end-tidal Pco2 during prolonged acetazolamide treatment in humans. Am J Physiol. 1990;258:H954-H959.","journal-title":"Am J Physiol"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1748-1716.1975.tb05827.x"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/jcbfm.1989.61"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1152\/jappl.1988.65.1.422"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1475-097X.1990.tb00792.x"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1748-1716.1985.tb00048.x"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.1981.sp013938"},{"key":"e_1_3_2_25_2","first-page":"1","volume":"106","year":"1960","unstructured":"Maren TH, Robinson B. The pharmacology of acetazolamide as related to cerebrospinal fluid and the treatment of hydrocephalus. Bull Johns Hopkins Hosp. 1960;106:1-24.","journal-title":"Bull Johns Hopkins Hosp"},{"key":"e_1_3_2_26_2","first-page":"197","volume":"5","year":"1970","unstructured":"Lehmann B, Linner E, Wistrand PJ. The pharmacokinetics of acetazolamide in relation to its use in the treatment of glaucoma and its effects as an inhibitor of carbonic anhydrases. Adv Biosci. 1970;5:197-219.","journal-title":"Adv Biosci"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600680323"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/jcbfm.1994.130"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0001-2998(85)80013-1"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.1990.1002087.x"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1161\/str.18.5.3629647"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1980.00500570037005"},{"key":"e_1_3_2_33_2","doi-asserted-by":"crossref","unstructured":"Ackerman RH Zilkha E Bull JWD Du Boulay GH Marshall J Ross Russell WA Symon L. The relationship of the CO2 reactivity of cerebral vessels to blood pressure and mean resting blood flow. Neurology. 1973;23;21-26.","DOI":"10.1212\/WNL.23.1.21"}],"container-title":["Stroke"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/01.STR.26.12.2302","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T22:14:26Z","timestamp":1715552066000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/01.STR.26.12.2302"}},"subtitle":["Dose, Serum Concentration, and Time Course of the Response to Acetazolamide"],"short-title":[],"issued":{"date-parts":[[1995,12]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[1995,12]]}},"alternative-id":["10.1161\/01.STR.26.12.2302"],"URL":"https:\/\/doi.org\/10.1161\/01.str.26.12.2302","relation":{},"ISSN":["0039-2499","1524-4628"],"issn-type":[{"value":"0039-2499","type":"print"},{"value":"1524-4628","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995,12]]},"assertion":[{"value":"1995-06-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"1995-09-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"1995-12-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}